Additional file 1: Figure S1. of DEF6 expression in ovarian carcinoma correlates with poor patient survival

  • Phui Ly Liew (Contributor)
  • Chih Yeu Fang (Contributor)
  • Yu-Chieh Lee (Contributor)
  • Yi-Chih Lee (Contributor)
  • Chi-Long Chen (Contributor)
  • Jan-Show Chu (Contributor)

Dataset

Description

Kaplan-Meier curves for overall survival in four histological subtypes of ovarian carcinoma patients according to DEF6, p16 and p53 expressions. A, Patients with high DEF6 expression (scores 2 and 3; n = 60) versus low DEF6 expression (scores 0 and 1; n = 15) in high-grade serous carcinoma. (H: high DEF6 expression; L: low DEF6 expression). B, Patients with high p16 expression (scores 2 and 3; n = 56) versus low p16 expression (scores 0 and 1; n = 18) in high-grade serous carcinoma. (H: high p16 expression; L: low p16 expression). C, Patients with aberrant p53 expression (scores 0 and 3; n = 62) versus insignificant p53 expression (scores 1 and 2; n = 12) in high-grade serous carcinoma. D, Patients with high DEF6 expression (scores 2 and 3; n = 20) versus low DEF6 expression (scores 0 and 1; n = 16) in mucinous carcinoma. (H: high DEF6 expression; L: low DEF6 expression). E, Patients with high p16 expression (scores 2 and 3; n = 32) versus low p16 expression (scores 0 and 1; n = 3) in mucinous carcinoma. (H: high p16 expression; L: low p16 expression). F, Patients with aberrant p53 expression (scores 0 and 3; n = 17) versus insignificant p53 expression (scores 1 and 2; n = 19) in mucinous carcinoma. G, Patients with high DEF6 expression (scores 2 and 3; n = 6) versus low DEF6 expression (scores 0 and 1; n = 22) in endometrioid carcinoma. (H: high DEF6 expression; L: low DEF6 expression). H, Patients with high p16 expression (scores 2 and 3; n = 17) versus low p16 expression (scores 0 and 1; n = 11) in endometrioid carcinoma. (H: high p16 expression; L: low p16 expression). I, Patients with aberrant p53 expression (scores 0 and 3; n = 9) versus insignificant p53 expression (scores 1 and 2; n = 19) in endometrioid carcinoma. J, Patients with high p16 expression (scores 2 and 3; n = 30) versus low p16 expression (scores 0 and 1; n = 11) in clear cell carcinoma. (H: high p16 expression; L: low p16 expression). K, Patients with aberrant p53 expression (scores 0 and 3; n = 10) versus insignificant p53 expression (scores 1 and 2; n = 31) in clear cell carcinoma. (ZIP 195 kb)
Date made availableAug 3 2016
PublisherUnknown Publisher

Cite this